Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
*Saint Louis University School of Medicine, Saint Louis, MO †Department of Pediatrics, Division of Gastroenterology, Stanford University Medical Center, Palo Alto, CA.
Dimple
D
Patel
K T
KT
Park
D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017046:Cost Savings; D017277:Drug Approval; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration
D059451:Biosimilar Pharmaceuticals